We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Generation of Dendritic Cell Precursors From Cord Blood Stem Cells

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00731744
Recruitment Status : Unknown
Verified August 2008 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : August 11, 2008
Last Update Posted : August 11, 2008
Information provided by:
National Taiwan University Hospital

Brief Summary:

There is a growing interest in generating dendritic cells (DCs) for using as vaccines. Several cytokines, especially stem cell factor (SCF) and FLT3-ligand (FL), have been identified as essential to produce large numbers of myeloid precursors and even to increase DC yield obtained by the action of granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor alpha (TNF-α). However, there are few studies on the effect of the early-acting cytokines, commonly used to expand CD34+ progenitor cells, on DC generation.

We have established a serious of functional analysis of maturated or immaturated DCs including surface markers screening or cytokine production. Here, we design this two-year project to evaluate the possible methodology in the generation of CD14+CD1a- and CD14- CD1a+ myeloid DC precursors from CD34+ cells. In the first year of the project, we will set up the standard protocol to generate DC precursors from cord blood stem cells. In the first step, we will isolate CD34+ cells from cord blood and amplify these cells. Purity of the CD34+ cell populations obtained will be greater than 90%. In the next step, these primary cultures of CD34+ cells will treat with early-acting cytokines such as GM-CSF and IL-4 to further induction into dendritic cells. Functional analysis of dendritic cells would be performed in this stage. In the second year of the project, we will further evaluate the induction of DCs by CD34+ stem cells could be affected by combination of mesenchymal stromal cells. These results of this research with CD34+-based DCs induction provide the basis for materials to develop the DC-based vaccine against viral and fungal infections, and might be a powerful tool in anti-tumor immunotherapy.

Condition or disease Intervention/treatment Phase
Normal Full-Term Deliveries Procedure: Normal full-term deliveries Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Generation of Dendritic Cell Precursors From Cord Blood Stem Cells
Study Start Date : January 2007
Actual Primary Completion Date : February 2007
Estimated Study Completion Date : December 2010

Intervention Details:
  • Procedure: Normal full-term deliveries
    Normal full-term deliveries by standard procedures according to institutional guidelines

Primary Outcome Measures :
  1. None, we isolate stem cells from cord blood. [ Time Frame: from CS operation to close ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal full-term deliveries

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00731744

Layout table for location contacts
Contact: Chien-Nan Lee, Associate Professor 886-2-23123456 ext 5166 leecn@ntu.edu.tw

Layout table for location information
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Chien-Nan Lee, ASSOCIATE PROFESSOR    886-2-23123456 ext 5166    leecn@ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Layout table for additonal information
Responsible Party: Chien-Nan Lee, National Taiwan Unviersity Hospital
ClinicalTrials.gov Identifier: NCT00731744    
Other Study ID Numbers: 200706003R
First Posted: August 11, 2008    Key Record Dates
Last Update Posted: August 11, 2008
Last Verified: August 2008